Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for their drug GTX-102 (apazunersen) as a treatment for Angelman syndrome. This designation, aimed at expediting the development and review of drugs for serious or life-threatening diseases, is based on positive preliminary clinical evidence from a Phase 1/2 study involving 74 patients. The study showed consistent developmental gains and improvements across multiple symptom domains in participants treated for up to three years. Enrollment for the global Phase 3 Aspire study, which began in December 2024, is on track to complete in 2025, while the Aurora study is expected to start later this year to evaluate GTX-102 in other Angelman syndrome genotypes and ages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.